Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?

Agrafiotis, Apostolos C; Van Schil, Paul E

Agrafiotis, Apostolos C; Van Schil, Paul E.

Affiliation

Agrafiotis AC; Department of Thoracic and Vascular Surgery, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.
Van Schil PE; Department of Thoracic and Vascular Surgery, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.

J Thorac Dis ; 15(7): 3519-3521, 2023 Jul 31.

Article in En | MEDLINE | ID: mdl-37559599

Key words

Non-small cell lung cancer (NSCLC); adjuvant therapy; epidermal growth factor receptor (EGFR); immune checkpoint inhibitors (ICI); neoadjuvant treatment; tyrosine kinase inhibitors (TKI)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Thorac Dis Year: 2023 Document type: Article Affiliation country: Belgium

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Thorac Dis Year: 2023 Document type: Article Affiliation country: Belgium